The purpose of this study is to investigate the safety and efficacy of the study drug in the treatment of bipolar I depression. The study drug has been approved by the U.S, Food and Drug Administration (FDA) for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder.
To be considered for participation into the study you must:
• be at least 18 and no more than 65 years of age at Visit 1
• give written informed consent
• have a diagnosis of bipolar I depression
• not have participated in a clinical research study in the past 6 months
The duration of the study will be approximately 9 weeks. During this period of time there will be about 7 visits.
Name: Sevie Kandefer